It appears no script is enabled within your browser. Please enable JavaScript to use this site.
Skip header and navigation
Home
View Selections:
0
Items
Help
Print
Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
https://arctichealth.org/en/permalink/ahliterature106576
Source
Vaccine. 2013 Dec 5;31(50):5989-96
Publication Type
Article
Date
Dec-5-2013
More detail
Author
Isabelle Rouleau
Gaston De Serres
Jean Philippe Drolet
Danuta M Skowronski
Manale Ouakki
Eveline Toth
Monique Landry
Suzanne Ménard
Rémi Gagnon
Author Affiliation
Centre hospitalier universitaire de Québec, Quebec City, Quebec, Canada.
Source
Vaccine. 2013 Dec 5;31(50):5989-96
Date
Dec-5-2013
Language
English
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage - adverse effects
Adolescent
Adult
Aged
Aged, 80 and over
Anaphylaxis - chemically induced - epidemiology
Canada
Child
Child, Preschool
Drug Combinations
Drug-Related Side Effects and Adverse Reactions - epidemiology - pathology
Female
Humans
Incidence
Influenza A Virus, H1N1 Subtype - immunology
Influenza Vaccines - administration & dosage - adverse effects
Influenza, Human - prevention & control - virology
Male
Middle Aged
Polysorbates - administration & dosage - adverse effects
Quebec
Risk assessment
Squalene - administration & dosage - adverse effects
Young Adult
alpha-Tocopherol - administration & dosage - adverse effects
Abstract
Anaphylaxis after trivalent influenza vaccination is typically reported at a rate of
PubMed ID
24144473
View in PubMed
Less detail
Permalink